Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity-Reference-Cited by-同舟云学术

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Published:2016-07-14 Issue:2 Volume:128 Page:195-203
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lampson Benjamin L.¹^ORCID,Kasar Siddha N.¹,Matos Tiago R.¹,Morgan Elizabeth A.²^ORCID,Rassenti Laura³⁴,Davids Matthew S.¹⁴,Fisher David C.¹,Freedman Arnold S.¹,Jacobson Caron A.¹,Armand Philippe¹,Abramson Jeremy S.⁵,Arnason Jon E.⁶,Kipps Thomas J.³⁴,Fein Joshua¹^ORCID,Fernandes Stacey¹⁴,Hanna John¹,Ritz Jerome¹^ORCID,Kim Haesook T.⁷^ORCID,Brown Jennifer R.¹⁴

Affiliation:

1. Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Pathology, Brigham and Women's Hospital, Boston, MA;

3. Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA;

4. CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;

5. Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;

6. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA; and

7. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Abstract

Key Points Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/2/195/1397296/195.pdf

Reference37 articles.

1. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract].;Sharman;Blood,2014

2. Update on a phase 1 study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia.;Coutre;Haematologica,2013

3. A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract].;De Vos;Blood,2013

Cited by 262 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Holding the therapy in CLLp53: mechanisms to achieve durable responses;Anti-Cancer Drugs;2024-08-09

2. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05

3. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial;Nature Medicine;2024-06-17

4. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas;Life Sciences;2024-06

5. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-04